• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Respiratory Society (ERS) 2021

September 5 - 8, 2021

  1. Tezepelumab
  2. Benralizumab
  3. Budesonide/Glycopyrronium/Formoterol (PT010)
  4. Formoterol
  5. NOVELTY
  6. International Severe Asthma Registry (ISAR)
  7. PRECISION
  8. CARBON
  9. Real-Word Evidence - Asthma
  10. Real-Word Evidence - COPD
  11. Real-Word Evidence - Chronic Rhinosinusitis with Nasal Polyposis
  12. Early R&D

HTML

Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patient with severe asthma

HTML

Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR

HTML

Effect of tezepelumab on exacerbation-related oral corticosteroid use in NAVIGATOR

HTML

Efficacy of tezepelumab in adolescents with severe, uncontrolled asthma

HTML

Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR

HTML

Effects of tezepelumab on host epithelial tolerance to virus in patients with uncontrolled asthma

HTML

Identifying super-responders to benralizumab in severe asthma

HTML

Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab

HTML

Characteristics of a real world cohort of Canadians treated with benralizumab

HTML

Early response to benralizumab in Canadians with severe eosinophilic asthma

HTML

Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase

HTML

Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study

HTML

Standard-of-Care Asthma Controller Regimen Reduction with Benralizumab Treatment: ANDHI In Practice Study

HTML

Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study

HTML

Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial  

HTML

Risk factors for all-cause mortality in patients with COPD: results from the ETHOS trial

HTML

Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS

HTML

The association between health-related quality of life and COPD exacerbations measured by EQ-5D-5L in the ETHOS trial

HTML

The relationship between eosinophils and reduction in major adverse cardiac events in ETHOS

HTML

Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial

HTML

Safety of as-needed formoterol in asthma patients on different maintenance long-acting β2-agonists

HTML

Treatable traits in the NOVELTY study: prevalence, patterns and relationship with physician-assessed severity

HTML

Treatable traits in the NOVELTY study: assessing complexity by network analysis

HTML

Eosinophilic phenotype classification of patients with asthma and/or COPD in NOVELTY

HTML

Distribution of biomarkers in severe asthma and severe uncontrolled asthma

HTML

A comparison of 129Xe MRI and advanced lung function testing in patients with asthma and/or COPD: The NOVELTY ADPro substudy

HTML

Baseline characteristics of severe asthma patients initiating biologic treatment worldwide

HTML

Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not

HTML

Comparative effectiveness of anti-IL5/5R versus anti-IgE in patients eligible for both (FIRE)

HTML

Assessing the Asthma Impairment and Risk Questionnaire’s ability to predict exacerbations

HTML

Pan-Canadian Respiratory Standards Initiative for Electronic Health Records (PRESTINE): Validation of a Severe Asthma Algorithm

HTML

Oral corticosteroid (OCS) risk predictor for osteoporosis

HTML

Severe asthma prevalence, care pathways, and health care resource utilization in France 

HTML

Short-acting β2-agonists and greenhouse gas emissions in Europe and Canada

HTML

Greenhouse gas emissions associated with asthma care in the UK: results from SABINA CARBON

HTML

Greenhouse gas emissions associated with COPD care in the UK: SHERLOCK CARBON

HTML

BREATHE – Distribution and co-expression of T2 biomarkers in asthma and association with severity, clinical characteristics and co-morbidities

HTML

Temporal change in pediatric asthma exacerbation rates - a nationwide Swedish asthma cohort (HERA)

HTML

Healthcare costs associated with short-acting β2-agonist use in asthma: an observational UK study from the SABINA global programme

HTML

Trends in asthma incidence in children: a UK population-based cohort study

HTML

Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions 

HTML

Annual systemic and inhaled corticosteroid exposures in US patients ≥4 years with asthma

HTML

The burden of intermittent oral corticosteroid use in asthma

HTML

Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE)

HTML

Burden of asthma by treatment step in the French CONSTANCES general population cohort

HTML

Real-world exacerbation rates in Japanese patients with COPD: results from the EXACOS observational cohort study

HTML

Increasing risk of exacerbation and mortality associated with increasing frequency and severity of exacerbations in COPD patients: EXACOS-UK

HTML

Projections of 10-year mortality in patients with COPD in the UK using the CHOPIN policy model

HTML

Ten-year projected outcomes associated with increased use of triple therapies in UK patients with COPD using the COPD Health Outcome Policy and INtervention (CHOPIN) model

HTML

Association between COPD exacerbations and acute cardiovascular events: a systematic literature review

HTML

Healthcare costs and resource use in patients with chronic obstructive pulmonary disease (COPD) in Ontario, Canada

HTML

Exacerbations in chronic obstructive pulmonary disease (COPD) in Ontario, Canada

HTML

Treatment patterns of patients with chronic obstructive pulmonary disease (COPD) in Ontario, Canada

HTML

REALizing and improving management of COPD in China: A prospective observational study

HTML

Disease trajectories in GOLD B chronic obstructive pulmonary disease (COPD) patients – nationwide data from Denmark

HTML

Relationship between clinical features and mortality in a cohort of COPD patients

HTML

Patient characteristics and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Canada

HTML

Real-world evidence of reported symptoms and quality of life burden associated with chronic rhinosinusitis with nasal polyposis and comorbid asthma

HTML

Smoking induces activation of the complement system in the small airways in a sex-specific manner

HTML

MicroRNA profiling in bronchial biopsies identifies altered expression in asthma and high levels of allergen-modulated epithelial microRNAs

HTML

Identification of HuR-specific RNA interactome in TGF-β1-activated fibroblasts in response to cigarette smoke

HTML

NETosis induced by haemophilus influenzae disrupts the lung epithelial barrier

HTML

Modeling idiopathic pulmonary fibrosis using induced pluripotent stem cell-derived alveolar epithelial organoids

HTML

The inflammasome cluster is linked with airway NETosis in COPD

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice